Hydrocortison Strides (Hydrocortisone)

Hydrocortison Strides is indicated for several conditions where cortisol replacement or anti‑inflammatory action is required.

• Adrenal insufficiency (primary or secondary) requiring glucocorticoid replacement.
• Acute or chronic inflammatory disorders such as arthritis, dermatitis, or ulcerative colitis.
• Severe allergic reactions, including anaphylaxis adjunct therapy.
• Certain autoimmune diseases where immunosuppression is beneficial.
• Management of adrenal crisis in emergency settings.
• Prevention of postoperative inflammation in patients undergoing major surgery.

• Hydrocortison Strides delivers hydrocortisone, a synthetic analogue of endogenous cortisol. The compound binds to intracellular glucocorticoid receptors, forming a receptor‑ligand complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokines. The net effect is reduced leukocyte migration, decreased capillary permeability, and inhibition of immune cell activation.

Like other systemic glucocorticoids, Hydrocortison Strides may cause a range of adverse reactions, which vary in frequency and severity, and can affect multiple organ systems.

Common

• Increased appetite or weight gain.
• Mild gastrointestinal discomfort such as nausea or dyspepsia.
• Fluid retention leading to peripheral edema.
• Mood changes including irritability or mild anxiety.
• Elevated blood glucose levels, especially in susceptible individuals.
• Skin thinning or easy bruising.
• Headache or dizziness.

Serious

• Severe infection due to immunosuppression.
• Significant hypertension or worsening of pre‑existing hypertension.
• Osteoporosis or increased risk of fractures with prolonged use.
• Adrenal suppression leading to crisis upon abrupt discontinuation.
• Psychiatric disturbances such as psychosis or severe depression.

Before initiating therapy with Hydrocortison Strides, clinicians should evaluate patient history and monitor for conditions that could be worsened by glucocorticoid exposure.

• Assess for active infections; treat before starting therapy.
• Review history of hypertension, diabetes, or osteoporosis.
• Consider bone density monitoring for long‑term use.
• Evaluate psychiatric history, as glucocorticoids may exacerbate mood disorders.
• Use the lowest effective dose for the shortest duration possible.
• Counsel patients on signs of adrenal insufficiency during tapering.
• Avoid use in patients with known hypersensitivity to hydrocortisone.

Hydrocortison Strides can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of key interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with potent CYP3A4 inducers such as rifampin, which may reduce hydrocortisone exposure.
• Simultaneous administration of strong CYP3A4 inhibitors (e.g., ketoconazole) that can increase systemic levels.
• Combining with other systemic glucocorticoids, which raises the risk of cumulative toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to increased gastrointestinal ulcer risk.
• Anticoagulants (e.g., warfarin) as glucocorticoids may enhance anticoagulant effect.
• Vaccines, especially live attenuated, because immunosuppression can diminish efficacy.